Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

A number of other research analysts have also weighed in on MBRX. Maxim Group dropped their price objective on Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 26th. Roth Mkm reaffirmed a “buy” rating and set a $40.00 price objective on shares of Moleculin Biotech in a report on Friday, April 12th.

Moleculin Biotech Stock Up 4.0 %

Shares of MBRX stock opened at $3.66 on Friday. The business’s fifty day moving average price is $4.51 and its 200 day moving average price is $6.86. Moleculin Biotech has a 1-year low of $3.35 and a 1-year high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings data on Friday, May 10th. The company reported ($2.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $1.57. As a group, equities research analysts anticipate that Moleculin Biotech will post -8.79 EPS for the current year.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Armistice Capital LLC bought a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned approximately 9.60% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). 15.52% of the stock is owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.